Table 5.
Odds of Thromboembolism and Hypertension Among Transwomen, by Hormone Prescriptions
| TE, Model 1 | Recent prescriptions |
History of prescriptions |
||||
|---|---|---|---|---|---|---|
| Unadjusted* | Adjusted** | Mediated*** | Unadjusted* | Adjusted** | Mediated*** | |
| Estrogen | 1.52 (0.44, 5.28), p=0.51 | 1.54(0.43, 5.47), p=0.50 | 1.57 (0.44, 5.59), p=0.49 | — | — | — |
| AA/finasteride | 0.94 (0.37, 2.35), p=0.88 | 1.25 (0.48, 3.26), p=0.65 | 1.21 (0.46, 3.17), p=0.70 | 1.07 (0.14, 8.13), p=0.94 | — | — |
| Progestin | 2.23 (0.80, 6.24), p=0.12 | 2.98 (1.03, 8.63), p=0.04 | 2.95 (1.02, 8.57), p=0.04 | 1.07 (0.41, 2.84), p=0.88 | — | — |
| TE, Model 2 | ||||||
| Estrogen-Oral | 1.37 (0.38, 5.01), p=0.63 | 1.49 (0.41, 5.39), p=0.54 | 1.46 (0.40, 5.26), p=0.56 | 1.10 (0.39, 3.14), p=0.85 | 1.13 (0.39, 3.25), p=0.82 | 1.24 (0.42, 3.61), p=0.69 |
| Estrogen-Patch | 3.07 (0.34, 28.0), p=0.32 | 2.04 (0.22, 19.1), p=0.53 | 1.71 (0.18, 16.5), p=0.64 | 1.40 (0.46, 4.26), p=0.55 | 1.01 (0.32, 3.18), p=0.98 | 0.95 (0.30, 3.01), p=0.92 |
| Estrogen-Injectable | 2.35 (0.68, 8.16), p=0.17 | 2.21 (0.62, 7.86), p=0.21 | 2.25 (0.65, 7.83), p=0.20 | 2.65 (0.75, 9.36), p=0.13 | 2.26 (0.61, 8.34), p=0.22 | 2.21 (0.60, 8.22), p=0.23 |
| AA/finasteride | 1.04 (0.41, 2.65), p=0.93 | 1.37 (0.52, 3.62), p=0.52 | 1.32 (0.50, 3.50), p=0.57 | 1.12 (0.15, 8.49), p=0.91 | 1.91 (0.24, 15.2), p=0.54 | 1.99 (0.24, 16.3), p=0.52 |
| Progesterone | 1.73 (0.57, 5.29), p=0.33 | 2.28 (0.72, 7.21), p=0.16 | 2.27 (0.72, 7.16), p=0.16 | 0.80 (0.28, 2.25), p=0.66 | 0.99 (0.34, 2.87), p=0.97 | 1.00 (0.34, 2.94), p=0.99 |
| MPA | 11.11 (1.35, 91.4), p=0.02 | 17.7 (1.97, 159.6), p=0.01 | 20.0 (2.14, 187.2), p=0.009 | 1.83 (0.24, 14.0), p=0.56 | 1.44 (0.18, 11.5), p=0.73 | 1.61 (0.20, 13.1), p=0.65 |
| HTN, Model 1 | ||||||
| Estrogen | 0.60 (0.29, 1.23), p=0.16 | 0.66 (0.31, 1.42), p=0.29 | 0.67 (0.31, 1.43), p=0.29 | 0.76 (0.09, 6.47), p=0.79 | 0.32 (0.04, 2.79), p=0.29 | 0.39 (0.04, 3.90), p=0.42 |
| AA/finasteride | 0.56 (0.30, 1.06), p=0.07 | 0.88 (0.45, 1.74), p=0.72 | 0.93 (0.47, 1.85), p=0.83 | 0.51 (0.21, 1.27), p=0.14 | 1.25 (0.48, 3.27), p=0.64 | 1.38 (0.52, 3.70), p=0.51 |
| Progestin | 0.47 (0.17, 1.35), p=0.16 | 0.59 (0.20, 1.74), p=0.34 | 0.56 (0.19, 1.67), p=0.30 | 0.32 (0.14, 0.77), p=0.01 | 0.35 (0.15, 0.85), p=0.02 | 0.36 (0.15, 0.87), p=0.02 |
| Testosterone | 1.37 (0.16, 11.6), p=0.76 | 2.30 (0.26, 20.3), p=0.46 | 1.86 (0.21, 16.6), p=0.57 | 2.00 (0.41, 9.85), p=0.39 | 2.05 (0.40, 10.4), p=0.38 | 2.06 (0.39, 10.8), p=0.39 |
| HTN, Model 2 | ||||||
| Estrogen-Oral | 0.44 (0.20, 0.99), p=0.04 | 0.49 (0.21, 1.14), p=0.09 | 0.52 (0.22, 1.20), p=0.12 | 0.61 (0.32, 1.14), p=0.12 | 0.59 (0.30, 1.16), p=0.12 | 0.68 (0.34, 1.35), p=0.26 |
| Estrogen-Patch | 1.09 (0.24, 5.00), p=0.91 | 0.55 (0.11, 2.72), p=0.46 | 0.38 (0.06, 2.26), p=0.28 | 2.01 (1.03, 3.93), p=0.04 | 1.17 (0.57, 2.41), p=0.66 | 1.18 (0.56, 2.49), p=0.66 |
| Estrogen-Injectable | 0.76 (0.36, 1.60), p=0.47 | 0.89 (0.40, 1.99), p=0.77 | 0.86 (0.39, 1.92), p=0.71 | 0.77 (0.42, 1.44), p=0.41 | 0.70 (0.35, 1.39), p=0.31 | 0.72 (0.35, 1.45), p=0.35 |
| AA/finasteride | 0.61 (0.33, 1.14), p=0.12 | 0.96 (0.49, 1.88), p=0.89 | 1.01 (0.51, 2.01), p=0.97 | 0.53 (0.21, 1.31), p=0.16 | 1.28 (0.49, 3.33), p=0.61 | 1.43 (0.53, 3.86), p=0.47 |
| Progesterone | 0.50 (0.18, 1.43), p=0.19 | 0.60 (0.20, 1.75), p=0.34 | 0.58 (0.19, 1.72), p=0.32 | 0.36 (0.15, 0.87), p=0.02 | 0.45 (0.18, 1.11), p=0.08 | 0.46 (0.18, 1.13), p=0.08 |
| MPA | — | — | — | 0.75 (0.10, 5.58), p=0.77 | 0.39 (0.05, 3.20), p=0.38 | 0.39 (0.05, 3.37), p=0.39 |
| Testosterone | 1.53 (0.18, 12.8), p=0.69 | 2.86 (0.32, 25.5), p=0.34 | 2.13 (0.24, 19.3), p=0.50 | 2.00 (0.44, 9.16), p=0.37 | 2.49 (0.52, 12.0), p=0.25 | 2.43 (0.51, 11.6), p=0.26 |
*
All hormones are included together in the unadjusted model.
**
Includes race, insurance, HIV status, and age.
***
Also includes BMI.
MPA, medroxyprogesterone acetate.